Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: The Value and Role of Anti-Angiogenesis in Solid Tumours and the Mechanism to Inhibit Angiogenesis

New module by Prof Fortunato Ciardiello, Dr Erika Martinelli, Dr Teresa Troiani, and Dr Valentina Gambardella out now. View the presentation and, if you are an ESMO member, take the CME test!

Learning objectives

  • To provide an update on neoangiogenesis in solid tumours and the value of its inhibition
  • To provide an update on anti-angiogenic agents, their mechanism of action, and the role they have in the management of various solid tumours
  • To summarise results from the clinical studies with anti-angiogenic agents in various solid tumours

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
The value and role of anti-angiogenesis in solid tumours and the mechanism to inhibit angiogenesis 33 min. 75 slides - -

Angiogenesis is a crucial mechanism required for many physiological events. Neoangiogenesis is a multistep process and in recent years the use of anti-angiogenic drugs has become wider practice in cancer therapy. Anti-angiogenic drugs demonstrated activity in different types of solid tumours, including colorectal, lung, breast, ovarian, gastric, hepatocellular, renal cell cancers, neuroendocrine gastro-entero-pancreatic tumours, and sarcomas.

This E-learning module provides an essential update on angiogenesis and mechanisms of neoangiogenesis, as well as describing the role that both processes have in the organism. Furthermore, it provides a list of principal pro- and anti-angiogenesis factors and describes VEGFR pathway.

The authors further segment the module according to agents targeting the VEGF pathway: anti-VEGF antibodies (bevacizumab), anti–VEGFR-2 antibodies (ramucirumab), soluble VEGF receptors (aflibercept), and principal small molecule inhibitors (sunitinib, sorafenib, pazopanib, and regorafenib).

For each of the above mentioned agents, the authors provide a comprehensive overview of relevant clinical studies in a range of solid tumours, in particular those in which the concept of anti-angiogenesis has shown clinically meaningful activity. Among the described different angiogenesis inhibitors, the authors underline that they share similar “class specific” adverse events such as hypertension, bleeding, thrombosis, fatigue, and hand and foot syndrome.

Finally, by providing key efficacy results, the authors touch the issue of a more personalised management and cover the current research results in term of biomarkers, concluding that better markers of efficacy are needed for anti-VEGF agents.

This E-Learning module was published in 2014 and expired in 2016.

Last update: 21 Aug 2014

F. Ciardiello has participated in advisory board with Roche, Merck Serono, Astellas and Bayer. E. Martinelli, V. Gambardella, T. Troiani have reported no conflict of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings